TABLE 1.
Characteristics of participants in the original cross-sectional cohort analyses
|
iatr paper update (N = 336) |
Cluster paper update (N = 237)a |
C4d and DSA paper update (N = 172) |
||||
|---|---|---|---|---|---|---|
| Number with data available | n (%) or mean (SD) | Number with data available | n (%) or mean (SD) | Number with data available | n (%) or mean (SD) | |
| Female gender | 336 | 177 (53) | 237 | 13 (54.6) | 172 | 84 (49) |
| Hispanic or Latino ethnicity | 335 | 4 (1.2) | 236 | 2 (0.8) | 172 | 0 |
| Race | ||||||
| Caucasian | 335 | 263 (78) | 236 | 188 (79.7) | 172 | 131 (76) |
| Black or African American | 335 | 46 (14) | 236 | 34 (14.4) | 172 | 25 (14) |
| Asian | 335 | 12 (3.6) | 236 | 6 (2.5) | 172 | 6 (3.5) |
| Native American/Aleutian Islander | 335 | 13 (3.9) | 236 | 7 (3.0) | 172 | 9 (5.2) |
| Multiracial | 335 | 1 (0.3) | 236 | 1 (0.4) | 172 | 1 (0.6) |
| Primary cause of kidney disease | ||||||
| Diabetes | 336 | 101 (30) | 237 | 72 (30) | 172 | 51 (30) |
| Glomerular disease | 336 | 94 (28) | 237 | 71 (30) | 172 | 48 (28) |
| Hypertensive nephrosclerosis | 336 | 33 (9.8) | 237 | 25 (11) | 172 | 23 (13) |
| Polycystic kidney disease | 336 | 24 (7.1) | 237 | 16 (7) | 172 | 9 (5.2) |
| Other | 336 | 67 (20) | 237 | 45 (19) | 172 | 32 (19) |
| Unknown | 336 | 17 (5.1) | 237 | 8 (3) | 172 | 9 (5.2) |
| Era | ||||||
| Before 1980 | 336 | 4 (1.2) | 237 | 3 (1.3) | 172 | 3 (1.7) |
| 1980–1989 | 336 | 22 (6.6) | 237 | 13 (5.5) | 172 | 9 (5.2) |
| 1990–1999 | 336 | 97 (29) | 237 | 68 (29) | 172 | 52 (30) |
| 2000–2005 | 336 | 213 (63) | 237 | 153 (65) | 172 | 108 (63) |
| At transplant | ||||||
| Diabetes | 335 | 138 (41) | 236 | 97 (41) | 171 | 73 (43) |
| Hypertension | 336 | 114 (34) | 237 | 91 (38) | 172 | 57 (33) |
| Retransplant | 336 | 52 (15) | 237 | 43 (18) | 172 | 27 (16) |
| Living donor transplant | 336 | 201 (60) | 237 | 149 (63) | 172 | 101 (59) |
| Donor age (y) | 295 | 37 (13) | 209 | 37 (13) | 151 | 36 (13) |
| Donor hypertension | 240 | 13 (5.4) | 162 | 7 (4.1) | 126 | 9 (7.1) |
| Number of HLA mismatches | 327 | 3.2 (1.7) | 231 | 3.1 (1.7) | 167 | 3.2 (1.6) |
| Class I mismatches | 327 | 2.1 (1.3) | 231 | 2.1 (1.2) | 167 | 2.1 (1.2) |
| Class II mismatches | 327 | 1.1 (0.7) | 231 | 1.0 (0.7) | 167 | 1.1 (0.7) |
| Last creatinine before 2006 (mg/dL) |
336 | 1.4 (0.3) | 237 | 1.4 (0.3) | 172 | 1.4 (0.3) |
| At biopsy | ||||||
| Creatinine (mg/dL) | 335 | 2.6 (1.5) | 237 | 2.6 (1.5) | 171 | 2.7 (1.6) |
| Recipient age (y) | 336 | 48 (14) | 237 | 47 (14) | 172 | 49 (14) |
| Time posttransplant (y) | 336 | 7.2 (5.9) | 237 | 7.0 (5.9) | 172 | 7.3 (6.1) |
| Cumulative cyclosporine exposure (y) | 307 | 4.0 (5.3) | 216 | 3.9 (5.0) | 160 | 4.4 (5.2) |
| Cumulative tacrolimus exposure (y) |
311 | 2.1 (2.8) | 220 | 2.0 (2.6) | 159 | 2.1 (3.0) |
| C4d + | 299 | 108 (36) | 208 | 83 (40) | 172 | 68 (40) |
| DSA + | 304 | 130 (43) | 220 | 99 (45) | 172 | 70 (41) |
DSA, donor specific antibody; iatr, inflammation in areas of atrophy; SD, standard deviation; y, years.
a
Data for the 7 small clusters are not shown (N = 25).